MESTASTOP SOLUTIONS
CREATING A DIFFERENCE BY UNDERSTANDING METASTASIS BIOLOGY AND ADDRESSING MUCH-NEEDED DISCOVERY AND DIAGNOSTIC EFFORTS
The most painful experience in cancer is not the death, but the anticipation of death, that both the patient and their loved ones go through. This is because cancer can spread or metastasise anytime, even after the best of surgery or chemotherapy, and life comes down to living between PET scans and Blood tests.
With the vision to stop this suffering by filling the gaps in the understanding of metastasis biology and targeting it the right way in clinical settings, an incredible venture, Mestastop Solutions came into existence in 2018. The startup has a two-pronged approach, to both identify this phenomenon early (diagnostics) and intervene with this process (discovery). Mestastop is focused on the spreading of cancer cells from one part of the body to the others, a process known as metastasis. Mestastop Solutions has been at the forefront of IP generation, creating unique proprietary platforms to help solve the problem of cancer metastasis by facilitating drug discovery and early predictive diagnosis.
WHAT’S UNIQUE ABOUT MESTASTOP?
All previous approaches to interfere with metastasis were focused on the initial steps of cells moving out of the tumour and always targeted the growing cells. Paradoxically, the moving and growing tumor cells are very different, and the concept of Mestastop is focused on the moving cells only, as they are the most relevant for metastasis. Also, the team has identified critical rate-limiting steps of metastasis that were neglected before and have validated both these new concepts in patient samples, which minimizes the chances of clinical failures.
WORK CULTURE – THE MAIN STRENGTH BEHIND MESTASTOP
The whole team at Mestastop works 8 – 9 hours a day, but they work together, i.e., they back each other, and it is always a collective success or a collective failure. Trust and belief in each other work wonders for them. Mestastop follows an open culture policy where a team of self-motivated people is working selflessly to make a difference. Here, everyone is a thought leader or is being groomed as a potential leader, and all are bound by a thread of passion and motivation; to change the central dogma around cancer treatment. The leading team focuses on just picking the people with the right mindset. Rest, everyone is on autopilot!
MESTASTOP’S IN FIVE WORDS
Intent – Courage – Diligence – Resilience – Integrity
CORPORATE ETHOS FOR CLIENTELE
The company is all set to test compounds for Biopharma on its platforms and profile them against metastasis and is currently in discussions with some MNCs and one Indian pharma. As for diagnostics, Mestastop has not covered this segment so far. Here, the research work cannot be based on ten patient samples and needs a much bigger sampling size. This project is ongoing, and soon Mestastop will enter the diagnostics field.
ENSURING CONSTANT GROWTH WITH R&D AND TECH ADVANCEMENTS
R&D is everything in this field! Mestastop began with a hypothesis, but then data educates the team as they learn from it and modify their views. R&D is what sustains successful biotech and differentiates the good from the lucky ones.
“The Science we are following would not have been possible but for the technology currently available in our hands, thanks to all the innovative companies who design instruments, reagents, and kits. We work with purified tumor cells, which would not have been possible in high throughput a few decades back if not for the recent technological advances. We are also trying to integrate various other technologies into our work and working on creating some partnerships”
asserted Dr. Debabani Roy Chowdhury, co-founder and director, sharing her views on the involvement of tech solutions in the firm.
MESTASTOP’S INSIGHTS ON INNOVATIONS
Innovation is nothing but challenging the status quo, asking questions not asked before and finding answers to them. For example, the node positivity status is the routine method of predicting the metastasis probability of a patient with a primary tumor but no visible metastasis. According to the data by the research team, negative node patients can still have metastasis, and conversely, node-positive patients need not have metastatic tumors all the time.
ACHIEVEMENTS & FUTURE PLANS
Since Mestastop introduced the concept of the wet lab in November 2019, it has successfully presented its work at six international conferences. The company has filed two international patent applications and it has even been recognised as the “Best Metastasis R&D Specialist, 2022” by Global Health and Pharma, based in the UK. Its unique strength in science has attracted key angels and investors, and Mestastop has successfully achieved three fundings from the Government of India.
While Mestastop has successfully navigated through the journey till now by generating data with courage and resilience, it is yet to measure miles. In the future, the company is planning to set itself as the innovative hub of India which will compete with the best in the world. Here, the focus is to establish a platform where talented Indians returning to India will pursue innovation from day one and impact people’s lives.
Must Read:-
- Top 10 pharma companies in the world
- Top 10 company of India 2021
- Top 10 logistic Companies in India
- Top 10 automobile companies in India
- Top 10 fastest growing industries in the world
- Top 10 most charitable person in the world, meet generous people
- Top 10 logistic Companies in India
- Top 10 Company in the Corporate World
- Top 5 Most Fuel Efficient Car In India
- Start Small and go Big: Low-Investment Business Ideas 2021
- Top 10 Electrical Company in India 2021
